Vanguard Fiduciary Trust’s Soleno Therapeutics SLNO Stock Holding History

Vanguard Fiduciary Trust’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-342,758	Closed	-$11.5M	–	4143
2026 Q1	$11.5M	Buy	+342,758	New	+$13.4M	﹤0.01%	1644

Vanguard Fiduciary Trust's SLNO Position: Q2 2026 in Review

Vanguard Fiduciary Trust sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 342,758 shares — an estimated $11.5M sold.

Vanguard Fiduciary Trust first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $11.5M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Vanguard Fiduciary Trust reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Vanguard Fiduciary Trust sold 342,758 Soleno Therapeutics shares in Q2 2026, an estimated $11.5M.
Vanguard Fiduciary Trust first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
Vanguard Fiduciary Trust's Soleno Therapeutics position peaked at $11.5M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.